UCHealth Begins Part three Trial for One other COVID Vaccine Colorado Springs Information

UCHealth is preparing to start a Phase 3 study for another COVID-19 vaccine, the third coronavirus vaccine study the Colorado hospital giant has conducted since the pandemic began.

This latest “investigational vaccine,” as UCHealth called it in a press release on Monday, is manufactured by Novavax. The study is supported by the National Institutes of Health.

UCHealth will begin recruiting participants for the final phase of the vaccine trials, a process that “will take approximately two months,” according to the system.

“This pivotal Phase 3 clinical trial in the US and Mexico is critical to building on the encouraging safety and immunogenicity data we have generated to date and ultimately demonstrating how well (the Novavax vaccine) works against COVID -19 works, “Novavax President for Research and Development Gregory M. Glenn said in a statement.

“We are grateful to the thousands of volunteers who are committed to participating in this important research.”

UCHealth continues to participate in a study for the AstraZeneca dose, another vaccine candidate that officials said is expected to receive approval in the coming weeks.

Another trial for the already approved Moderna vaccine was completed in late October.

Phase 3 studies are usually the largest and final initial study of vaccines and other drugs. It will include thousands of patients in Colorado and Mexico, the hospital system said in its announcement.

Two-thirds of the UCHealth participants in this last study will receive a dose of the vaccine candidate, while one-third will receive a placebo.

“The focus of the Novavax Phase 3 trial is on demonstrating the safety and effectiveness of the vaccine in people who are at greatest risk of developing and getting sick with COVID-19,” the system wrote.

“UCHealth will also be recruiting people into at-risk groups, including study participants from the Blacks, Hispanic, Native American and Alaskan people, as well as those with certain health conditions, including those over 65 and those with diabetes, obesity, heart disease and lung disease or chronic Kidney disease. “

The results of the first and second phase studies, which began in May, were published last month in the New England Journal of Medicine. The report’s authors wrote that none of the participants had no “serious adverse events”.

The initial phase of the vaccine study consisted of two injections per patient; The Moderna and Pfizer vaccines also require two doses.

These two vaccines were approved in December and are available across Colorado and across the country.

Officials have announced that they expect two more vaccines – one from AstraZeneca and one from Johnson & Johnson – to be approved soon to further advance the country’s vaccine adoption.

Comments are closed.